Digestive Diseases News
-
GI Dynamics Announces Final Data from the ENDO Trial, a Multicenter Study Demonstrating the Potential Use of EndoBarrier to Treat Type II Diabetes and Obesity.
Initial results show the duodenal jejunal bypass liner (DJBL) technology met overall glycemic control efficacy and SAE related device removal safety endpoints Findings Presented at DDW 2022 BOSTON – June 15, 2022 – GI Dynamics, a medical device company that is developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and obesity, announced results from a ...
-
Posters Presented at DDW 2022 Demonstrate G-Tech System Motility Measurements Correlate with Antroduodenal Manometry Measurements and Can be Used to Characterize Colon Motility Alteration
MOUNTAIN VIEW, Calif., May 26, 2022 – G-Tech Medical, a developer of non-invasive diagnostic solutions for patients with gastrointestinal disorders, today announced that two posters were presented at Digestive Disease Week Conference held in San Diego in from May 21 through May 24. The first poster, entitled Wireless non-invasive patches detect phase III of the migrating motor complex in ...
-
Second Genome Presents New Data at Digestive Disease Week (DDW) 2022 Demonstrating that SG-5-00455, a Potential First-in-Class Precision Therapeutic, Improves Epithelial Barrier Function and Promotes Mucosal Healing in Inflammatory Bowel Disease
Lead development candidate SG-5-00455 shows potential to become first in class PAI-1/2 inhibitor that directly targets mucosal healing in patients with inflammatory bowel disease (IBD) Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, presented data demonstrating the Company’s development candidate, ...
-
Seres Therapeutics Presents Phase III Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 22, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome company, today announced the presentation of data from its Phase 3 ECOSPOR III study that suggest investigational microbiome-based therapeutic SER-109 prevents recurrent C. difficile infections (rCDI) by rapidly establishing a long-lasting colony of beneficial gut microbes, which can ...
-
ImmunogenX Highlighted at Pre-Eminent Celiac Disease Conference
On the basis of clinical success and acknowledged leadership in the field of celiac disease, the organizers of the International Celiac Disease Symposium (ICDS) have invited Jack Syage PhD, CEO of ImmunogenX, to deliver a panel talk and join the Conference Faculty. ICDS is held internationally every other year and is considered the premier conference for celiac disease. This year it will be held ...
-
Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 10, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present data from its ECOSPOR III trial of SER-109 at the Digestive Disease Week® (DDW) Annual Meeting, which is taking place May 21-24, 2022. SER-109 is an investigational oral microbiome therapeutic for the prevention of ...
-
Screening Subjects for Diabetic Peripheral Neuropathy
How much do you know about the development of your favorite products? What about the devices you encounter at your doctor’s office? So much of the work that goes into every single thing we use remains unseen by the user or consumer, from concept development to design to ...
-
AVM Biotechnology Awarded $1.6 Million Phase II SBIR Grant to Study AVM0703’s Potential to Reverse Type 1 Diabetes
AVM Biotechnology, LLC, a clinical stage company advancing AVM0703 in the treatment of Non-Hodgkin’s Lymphoma (NHL)/Leukemia, today announced that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant. This $1.6 million award from the National Institute of Diabetes and Digestive Kidney Disease (NIDDK) will allow the company to pursue additional research in the use ...
-
CoapTech LLC Awarded $1.2M Grant from National Institutes of Health to Support Clinical Evaluation and Training for Novel PUMA-G Device
CoapTech LLC announced today that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) within the National Institutes of Health (NIH) awarded the company a two-year, $1.2M R44 Small Business Innovation Research (SBIR) Phase II grant on August 29, 2019. This builds on a $225,000 Phase I SBIR R43 grant and a $200,000 Maryland Industrial Partnerships (MIPS) grant awarded to ...
By CoapTech
-
Creative Enzymes Probiotics Expands Service Offering with the Launch of Lactobacillus Strains
Creative Enzymes, a professional and experienced supplier of enzymes, has gained a great reputation in the industry. With the continuous expansion of business areas and scale, the company has set foot in other areas and established a sound probiotic production and supply chain. Relying on long-term professional lactic acid bacteria research results, Creative Enzymes brings highly acclaimed ...
-
ImmunogenX to Make Highlighted Presentations at DDW 2022
Based on the results obtained from the CeliacShieldTM trial (NCT03585478) by ImmunogenX, Inc. and conducted at the Mayo Clinic, the work has been selected as a Lecture Presentation at the 2022 Digestive Disease Week® (DDW) Conference, the foremost gastroenterological event in the world, being held at the San Diego Convention Center, San Diego, CA on May 21-24. The presentation entitled: ...
-
Omega Medical Imaging Announces Installation of AI Image-Guided Interventional Endoscopy Systems at Orlando Health
Sanford, Florida (February 21, 2022) — Omega Medical Imaging, the leading innovator in AI image-guided interventional systems for hospitals and healthcare facilities around the world, announced the installation of E-View.AI interventional endoscopy systems at Orlando Health. Located in downtown Orlando, the Orlando Health Digestive Health Institute is a national and international ...
-
Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics Landscape
Vaccitech plc (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced it will host a virtual Key Opinion Leader (“KOL”) event on VTP-300, in development as a key component of a functional cure therapy for chronic hepatitis B (CHB) infection, and the broader CHB therapeutics ...
-
Check-Cap Announces Publication of Peer-Reviewed Article Highlighting Safety and Patient Satisfaction Data for its Colorectal Screening Test, C-Scan
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced the publication of research titled "Colorectal cancer and polyp detection ...
-
Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection
RBX2660 pivotal Phase 3 trial successfully met the primary endpoint; data presented today at Digestive Disease Week® (DDW) RBX2660 is the first microbiota-based live biotherapeutic to demonstrate efficacy as early as first recurrence of Clostridioides difficile (C. difficile) infection RBX2660 Phase 3 data add to the world’s largest and most robust clinical program ever conducted in ...
-
CoapTech Awarded $1.6 Million from NIH for Pediatric Feeding Tube Placement Device
CoapTech Inc. announced today that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) within the National Institutes of Health (NIH) awarded CoapTech a two-year, $1.6M R44 Small Business Innovation Research (SBIR) Phase II grant on September 22, 2020 to finalize development of and trial its Pediatric PUMA-G System. This new grant builds on a prior $225,000 Phase I SBIR ...
By CoapTech
-
Lung Therapeutics Receives SBIR Award for Kidney Fibrosis Research; Principal Investigator BreAnne Mackenzie Will Speak at 4th Annual IPF Summit 2020/Digital
Lung Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for orphan, pulmonary indications, has been awarded a Small Business Innovation Research (SBIR) Grant of $300,228 from the National Institutes of Health (NIH) to study potential therapies that target fibrotic processes in the kidneys. Addressing an Unmet Medical Need There is a great need for ...
-
Symberix Awarded Multiple Grants from National Institutes of Health to Expand Platform of Microbiome-Targeted Drugs
Symberix, a preclinical stage company dedicated to the development of novel pharmaceutical treatments for lower gastrointestinal (GI) disorders, has been awarded two Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH). The two SBIR grants collectively totaling over $1.5 million are awarded by the NIH’s National Center for Advancing Translational ...
-
EndoClot Expands GI Hemostasis Portfolio With Launch of EndoClot® Adhesive
EndoClot Plus, Inc., a privately held medical device company founded by surgeons and biomaterial scientists announces the CE approval of EndoClot® Adhesive manufactured by EndoClot Plus Co., Ltd. located in Suzhou, China. The product will be made available for discussion during the upcoming Digestive Disease Week held in Washington DC, June 2-5, 2018. EndoClot® Adhesive is a single-use ...
-
Healionics Awarded $1.7M SBIR Grant from NIH to Advance New Vascular Graft Toward First-In-Human Use
Healionics Corporation, a Seattle-based medical device company, has received notice from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of a $1.7M Fast-Track Small Business Innovation Research (SBIR) grant in support of regulatory approval and a clinical study of STARgraftTM, its innovative synthetic vascular graft. Andrew Marshall, Healionics’ Chief Technology ...
By Healionics
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you